JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Candelore, M. R.
Right arrow Articles by Weber, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Candelore, M. R.
Right arrow Articles by Weber, A. E.

Vol. 290, Issue 2, 649-655, August 1999

Potent and Selective Human beta 3-Adrenergic Receptor Antagonists

Mari Rios Candelore, Liping Deng, Laurie Tota, Xiao-Ming Guan, Angela Amend, Yong Liu, Ron Newbold, Margaret A. Cascieri and Ann E. Weber

Department of Molecular Pharmacology/Immunology and Rheumatology, and Department of Medicinal Chemistry (R.N., A.E.W.), Merck & Co., Rahway, New Jersey

Although the functional presence of beta 3-adrenergic receptors (beta 3-AR) in rodents is well established, its significance in human adipose tissue has been controversial. One of the issues confounding the experimental data has been the lack of potent and selective human beta 3-AR ligands analogous to the rodent-specific agonist BRL37344. Recently, we described a new class of aryloxypropanolamine beta 3-AR agonists that potently and selectively activate lipolysis in rhesus isolated adipocytes and stimulate the metabolic rate in rhesus monkeys in vivo. In this article, we describe novel and selective beta 3-AR antagonists with high affinity for the human receptor. L-748,328 and L-748,337 bind the human cloned beta 3-AR expressed in Chinese hamster ovary (CHO) cells with an affinity of 3.7 ± 1.4 and 4.0 ± 0.4 nM, respectively. They display an affinity of 467 ± 89 and 390 ± 154 nM for the human beta 1-AR. Their selectivity for human beta 3-AR versus beta 2-AR is greater than 20-fold (99 ± 43 nM) and 45-fold (204 ± 75 nM), respectively. These compounds are competitive antagonists capable of inhibiting the functional activation of agonists in a dose-dependent manner in cells expressing human cloned beta 3-AR. Moreover, both L-748,328 and L-748,337 inhibit the lipolytic response elicited by the beta 3-AR agonist L-742,791 in isolated nonhuman primate adipocytes. The aryloxypropanolamine benzenesulfonamide ligands illustrated here and elsewhere demonstrate high-affinity human beta 3-AR binding. In addition, we describe specific 3'-phenoxy substitutions that transform these compounds from potent agonists into selective antagonists.

0022-3565/99/2902-0649$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. Wuest, B. Eichhorn, M. O. Grimm, M. P. Wirth, U. Ravens, and A. J. Kaumann
Catecholamines Relax Detrusor through {beta}2-Adrenoceptors in Mouse and {beta}3-Adrenoceptors in Man
J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 213 - 222.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Sato, D. S. Hutchinson, B. A. Evans, and R. J. Summers

Mol. Pharmacol., November 1, 2008; 74(5): 1417 - 1428.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
V. Leblais, E. Delannoy, F. Fresquet, H. Begueret, N. Bellance, S. Banquet, C. Allieres, L. Leroux, C. Desgranges, A. Gadeau, et al.
{beta}-adrenergic relaxation in pulmonary arteries: preservation of the endothelial nitric oxide-dependent {beta}2 component in pulmonary hypertension
Cardiovasc Res, January 1, 2008; 77(1): 202 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Sato, T. Horinouchi, D. S. Hutchinson, B. A. Evans, and R. J. Summers
Ligand-Directed Signaling at the beta3-Adrenoceptor Produced by 3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate (SR59230A) Relative to Receptor Agonists
Mol. Pharmacol., November 1, 2007; 72(5): 1359 - 1368.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
B. Rozec, S. Serpillon, G. Toumaniantz, C. Seze, Y. Rautureau, O. Baron, J. Noireaud, and C. Gauthier
Characterization of Beta3-Adrenoceptors in Human Internal Mammary Artery and Putative Involvement in Coronary Artery Bypass Management
J. Am. Coll. Cardiol., July 19, 2005; 46(2): 351 - 359.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K. Fricke, A. Schulz, H. John, W.-G. Forssmann, and E. Maronde
Isolation and Characterization of a Novel Proopiomelanocortin-Derived Peptide from Hemofiltrate of Chronic Renal Failure Patients
Endocrinology, April 1, 2005; 146(4): 2060 - 2068.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. S. Hutchinson, M. Sato, B. A. Evans, A. Christopoulos, and R. J. Summers
Evidence for Pleiotropic Signaling at the Mouse {beta}3-Adrenoceptor Revealed by SR59230A [3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol Oxalate]
J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1064 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Tatsumi, J. M. Engles, T. Ishimori, O. Nicely, C. Cohade, and R. L. Wahl
Intense 18F-FDG Uptake in Brown Fat Can Be Reduced Pharmacologically
J. Nucl. Med., July 1, 2004; 45(7): 1189 - 1193.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
A. Morimoto, H. Hasegawa, H.-J. Cheng, W. C. Little, and C.-P. Cheng
Endogenous {beta}3-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure
Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2425 - H2433.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
K. S. Banwait and S. Rattan
Role of nitric oxide in {beta}3-adrenoceptor activation on basal tone of internal anal sphincter
Am J Physiol Gastrointest Liver Physiol, August 8, 2003; 285(3): G547 - G555.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. N. K. Sarma, K. Banwait, A. Basak, A. J. DiMarino, and S. Rattan
Inhibitory Effect of beta 3-Adrenoceptor Agonist in Lower Esophageal Sphincter Smooth Muscle: In Vitro Studies
J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 48 - 55.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
S. Guimaraes and D. Moura
Vascular Adrenoceptors: An Update
Pharmacol. Rev., June 1, 2001; 53(2): 319 - 356.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.